Home > Startups > Vendors > Biologica Technologies

Biologica Technologies: Innovative Biologic Offerings for Faster Bone Regeneration

Follow Biologica Technologies on :

Amit Govil, President

Imagine an eighty-year-old with multiple nonunions in his ankle going through three surgeries using different orthobiologic products, and still not getting a successful fusion; painful, isn’t it? Such has been the shortcoming of many such products available in the orthopedic market today. “The underlying science is outdated, and there’s a lot of room for advancement, and that’s exactly what we do,” says Amit Govil, the president of Biologica Technologies. “Ten years ago, our affiliated company, Advanced Biologics, redefined the efficacy of allograft bone by developing and launching OsteoAMP® into the market. Now with the introduction of the ProteiOS® line of products, Biologica Technologies has reset the bar once again and surpassed greatly from their previous achievements.” The company focuses on redefining antiquated technologies and improving their efficacy by increasing their bioactivity. “Through our technology, we have developed innovative and novel methods to better access the naturally occurring growth factors found within allograft tissue,” mentions Govil.

Spun out from Advanced Biologicsin 2015, Biologica has been developing a number of orthopedic offerings utilizing its proprietary technologies. The first product the company brought to the market is ProteiOS growth factor, indicated for bone growth. “It is a soluble protein cocktail derived from the endosteum of allograft bone containing a collection of growth factors, oxygenating peptides, collagen deposition peptides, and cellular attachment peptides,” states Govil.

The underlying science is outdated, and there’s a lot of room for advancement, and that’s exactly what we do

Biologica has developed a product with the highest amount of non-recombinant BMP-2, 4, 6, 7, 9 along with the highest levels of non-recombinant PDGF-BB, VEGF, TBFβ-1, IGF-1, and HGF available on the market, available individually or in combination. ProteiOS is purified and packaged under nitrogen gas, and terminally irradiated where it can be used in the OR to stimulate bone growth in a particular area. Each lot of ProteiOS is tested and must meet minimum requirements for protein content for clinical release. What differentiates ProteiOS from other orthobiologics is that, unlike the other growth factor options available in the market, ProteiOS contains many components required for successful tissue regeneration and negates the need to use products with many side-effects. This has led to the creation of a safer product for stimulating bone growth through implantation.

Functioning as more than just a single growth factor or peptide, ProteiOS contains over 600 proteins, identified by mass spectroscopy and ELISA. When added to a synthetic scaffold, ProteiOS displays high growth factor and peptide binding when measured at 15 minutes and also exhibits a long-term sustained release versus the high initial “burst release” of rhBMP-2. “We are able to remove any immunological components from the tissue itself while providing the only sterile growth factor product available within the orthobiologics space,” says Govil.

Having carved a unique niche for itself by improving patients’ lives and the health care providers’ experience through innovative biologic solutions, Biologica has today has been leading the tissue science evolution. The company’s innovation labs continue to develop novel technologies further advancing options within the orthobiologics market.

Share this Article:

Company
Biologica Technologies

Headquarters
Carlsbad, CA

Management
Amit Govil, President

Description
Founded in 2015, Biologica works to find new and better ways to increase efficacy in orthobiologics by leveraging its proprietary technology. The company’s proprietary technology captures naturally occurring growth factors found within allograft tissue, providing patients and surgeons with novel biologic solutions. The company has been developing a number of orthopaedic initiatives involving our proprietary processing methodologies. The company’s primary product, ProteiOS growth factor possesses an array of osteoinductive, chemotactic, angiogenic and mitogenic growth factors that can be added to enhance a surgeon's scaffold of choice